First Trimester Screening for Preeclampsia & Intrauterine Growth

Status Completed

Clinical Trial Summary

Introduction: Preeclampsia (PE) and intrauterine growth restriction (IUGR) are two major pregnancy complications, related to a chronic utero-placental hypoperfusion. Nowadays, there isn't a screening or diagnostic test in clinic for utero-placental vascularization deficiency. Since 2004, 3D Power Doppler angiography has been used for the evaluation of utero-placental vascularisation and three vascular indices have been calculated: the vascularisation index (VI), flow index (FI) and vascularisation-FI (VFI). A high intra and inter-observer reproducibility and its potential interest for placental function study were reported. The investigator's main hypothesis is that these 3DPD indices could provide predictive values for PE and/or IUGR occurrence much higher than those observed with the currents other markers. Objectives: The main objective of this study is to determine differences in 3DPD indices at first trimester between pregnancies defined at their outcome as uncomplicated pregnancy, PE (mild and severe) and IUGR in nulliparous women. Methods and analysis: This is a prospective study. The investigators expect to include 2200 women in 4 French centers: Centre Hospitalier Universitaire de Nancy, Paris-Port-Royal (Assistance Publique - Hôpitaux de Paris), Strasbourg and Belfort (Hôpital Nord Franche-Comté). The nulliparous pregnant women will be recruited during their 1st trimester consultation for routine Down syndrome screening (11-13+6 gestation weeks). Especially for the study, the 3DPD and Uterine Artery Doppler (UAD) acquisition, which last less than 10 min, will be included in the current routine 11-13+6 gestation weeks ultrasound screening. Also, additional blood samples will be taken for biomarker analysis (PAPP-A and P1GF) and biological collection. Utero-placental vascularization indices (VI, FI, VFI) will be quantified using VOCAL® software. For each subgroup (uncomplicated pregnancy, PE and IUGR) mean values in 3DPD indices will be computed and compared using a pairwise t test with a Bonferroni correction p value adjustment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03342014
Study type	Interventional
Source	Central Hospital, Nancy, France
Contact
Status	Completed
Phase	N/A
Start date	April 16, 2018
Completion date	November 14, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03299777` - Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan	N/A
Completed	`NCT03650790` - C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies	N/A
Recruiting	`NCT03605511` - TTP and aHUS in Complicated Pregnancies
Not yet recruiting	`NCT03302260` - Identifying Methods for Postpartum Reduction of Vascular Events: Pilot Randomized Controlled Trial	N/A
Completed	`NCT02911701` - Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features	Phase 4
Completed	`NCT01911494` - Community Level Interventions for Pre-eclampsia	N/A
Terminated	`NCT02025426` - Phenylephrine Versus Ephedrine in Pre-eclampsia	Phase 4
Completed	`NCT01352234` - Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia	Phase 4
Active, not recruiting	`NCT02031393` - Establishing First Trimester Markers for the Identification of High Risk Twin	N/A
Terminated	`NCT00141310` - Sildenafil Citrate for the Treatment of Established Pre-Eclampsia	Phase 2
Completed	`NCT00157521` - L-Arginine in Pre-Eclampsia	Phase 3
Completed	`NCT04795154` - Prenatal Yoga as Complementary Therapy of Preeclampsia	N/A
Completed	`NCT00004399` - Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia	N/A
Completed	`NCT00005207` - Renin and Prorenin in Pregnancy	N/A
Recruiting	`NCT04551807` - Natural Versus Programmed Frozen Embryo Transfer (NatPro)	Phase 3
Terminated	`NCT04092829` - Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer	N/A
Recruiting	`NCT06067906` - Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients	N/A
Recruiting	`NCT06317467` - Role of Anti-C1q Autoantibodies in Pregnancy
Completed	`NCT02218931` - ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes	N/A
Active, not recruiting	`NCT04484766` - Preeclampsia Associated Vascular Aging

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

First Trimester Screening for Preeclampsia and Intrauterine Growth RestrIction Using Three Dimensional Doppler Angiography — SPIRIT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms